Compass Therapeutics reports phase 1 data for CTX-8371
Compass Therapeutics announced positive phase 1 data for its bispecific antibody CTX-8371 in advanced cancer patients, showing responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer. Despite these clinical results, the company's stock has declined significantly year-to-date, and analysts have mixed opinions on its prospects following recent study data for another drug candidate, tovecimig. The new CTX-8371 data will be presented at the American Society of Clinical Oncology Annual Meeting on May 30, 2026.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics will present promising Phase 1 clinical data for its novel dual checkpoint blocker, CTX-8371, at the 2026 ASCO Annual Meeting. The drug showed deep and durable responses in patients with advanced cancers like triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, particularly those resistant to prior immune checkpoint inhibitors. CTX-8371 was also well-tolerated with a favorable safety profile, leading to planned cohort expansions for further data reporting in Q4 2026.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics will present promising Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, at the 2026 ASCO Annual Meeting. The data show that CTX-8371 demonstrated clinical activity and was well-tolerated in patients with advanced malignancies resistant to prior immune checkpoint inhibitors, including deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer. The company plans to initiate cohort expansions in these malignancies, anticipating further data by Q4 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (NASDAQ: CMPX) on behalf of its investors. The investigation follows a significant 64.41% drop in Compass's stock price on April 27, 2026, after the company announced phase 2/3 study results for its drug tovecimig, which met a key secondary endpoint but missed another vital endpoint, overall survival. Investors who suffered losses are encouraged to contact the firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ...
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (NASDAQ: CMPX) on behalf of investors. This investigation follows a significant drop in Compass's stock price after the company announced phase 2/3 study results for its drug tovec. While the study met a key secondary endpoint, it missed another key secondary endpoint for overall survival, leading to a 63.61% stock decrease on April 26, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (NASDAQ:CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which, despite meeting a key secondary endpoint, missed another crucial one related to overall survival. Investors are encouraged to contact the firm regarding their legal rights.
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M
Compass Therapeutics (CMPX) reported a Q1 2026 net loss of $18.3 million, or $0.10 per share, with increased R&D and G&A expenses. The company holds $195 million in cash, providing a capital runway into 2028. Key developments include advancing tovecimig for biliary tract cancer with an upcoming BLA submission and FDA meeting, and initiating studies for CTX-8371, CTX-10726, and CTX-471.
5 Best NASDAQ Stocks Under $5 to Buy Right Now
The article lists the top 5 NASDAQ stocks under $5 to consider buying. It highlights Compass Therapeutics Inc. (NASDAQ: CMPX) as one such stock, detailing its recent financial performance, R&D activities, and clinical trial progress for various oncology treatments, including orphan drug designation for tovecimig. The company reports a capital runway into 2028 and has several studies underway.
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11
This article reports a significant 26.39% decrease in the price target for Compass Therapeutics (CMPX), bringing it down to $10.11. The financial adjustment suggests a revised outlook on the company's future performance or valuation.
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11
The article reports that Compass Therapeutics (CMPX) has had its price target decreased by 26.39%, bringing the new target to $10.11. This adjustment indicates a notable shift in analyst expectations for the company's stock performance.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Compass Therapeutics, Inc. (CMPX) following a significant stock price drop. This occurred after the company announced results from a phase 2/3 study for its drug tovecimig, which met a key secondary endpoint but missed another crucial one related to overall survival. The law firm is encouraging affected shareholders to join their investigation.
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, announced its participation in two investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ and the 2026 Stifel Virtual Targeted Oncology Forum. Company management will be available for one-on-one meetings, and presentations will be archived on Compass' Events page.
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics, Inc. announced its participation in two investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ and the 2026 Stifel Virtual Targeted Oncology Forum. Management will be available for one-on-one meetings, and presentations will be archived online. The company is a clinical-stage biopharmaceutical firm focused on developing antibody-based therapeutics for oncology.
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, announced its participation in two investor events in May: the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, and the 2026 Stifel Virtual Targeted Oncology Forum on May 20, 2026. Management will be available for one-on-one meetings, and presentations will be archived on the company's events page. Compass Therapeutics is developing proprietary antibody-based therapeutics targeting angiogenesis, immune activation, and reduction of tumor-driven immunosuppression.
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics, Inc. announced its participation in two investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19th and the 2026 Stifel Virtual Targeted Oncology Forum on May 20th. The company, a clinical-stage biopharmaceutical firm focused on oncology, will have its management available for one-on-one meetings during these virtual events. Presentations will also be archived on Compass' Events page for later viewing.
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 Stifel Virtual Targeted Oncology Forum. The company's management will be available for one-on-one meetings, and presentations will be archived on their events page.
Compass Therapeutics(CMPX) Stock Options Chain | Quotes & News
This document appears to be a stub or an empty page related to Compass Therapeutics (CMPX) stock options chain, quotes, and news. There is no substantive content provided beyond the title.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Compass Therapeutics, Inc. (NASDAQ:CMPX) investors. This investigation follows a significant 64.41% drop in Compass's stock price after a Phase 2/3 study for its drug tovecimig met one key secondary endpoint (progression-free survival) but missed another crucial one (overall survival). Investors are encouraged to visit bgandg.com/CMPX to learn more and assist with the investigation.
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Compass Therapeutics, Inc. (CMPX) after the Company's stock price dropped significantly. This follows an announcement of Phase 2/3 study results for its drug tovecimig, which, despite meeting a key secondary endpoint, missed another for overall survival. The law firm is encouraging affected shareholders to contact them to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from an April 27, 2026, announcement regarding a phase 2/3 study for its drug tovecimig, where the study missed a key secondary endpoint of overall survival, despite meeting the progression-free survival endpoint. Investors who purchased Compass securities are encouraged to contact the firm for additional information.
Craig-Hallum Maintains Compass Therapeutics(CMPX.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating on Compass Therapeutics (CMPX.US). This endorsement suggests a continued positive outlook on the company's stock performance from the analyst firm.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) after its stock price dropped significantly. This follows the announcement of mixed results from a phase 2/3 study for its drug tovecimig, which met one key secondary endpoint but missed another. The firm is encouraging affected investors to connect and assist with the investigation.
Compass Therapeutics 4Q Research and Development Expenses $13.4M >CMPX
Compass Therapeutics reported research and development expenses of $13.4 million for the fourth quarter. This financial detail is significant for investors following the company's operational expenditures. The information is concise, focusing solely on this key financial metric.
Compass Therapeutics (Nasdaq:CMPX) - Stock Analysis
This article provides a detailed stock analysis for Compass Therapeutics (CMPX), a clinical-stage oncology-focused biopharmaceutical company. It covers valuation, future growth, and financial health, noting that the stock is trading significantly below its estimated fair value with earnings forecast to grow substantially. The report also highlights recent positive clinical trial results for Tovecimig in biliary tract cancer and outlines various risks including share price volatility, past shareholder dilution, and current unprofitability.
Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics has reported its first-quarter financial results for 2026, alongside a corporate update. The company provided details on its financial performance and outlined key developments within its operations for the period.
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics (Nasdaq: CMPX) reported its first quarter 2026 financial results, highlighting positive data from its Phase 2/3 study of tovecimig for biliary tract cancer, with plans for a Biologics License Application (BLA) submission later this year. The company also provided updates on its other bispecific antibody candidates, CTX-8371 and CTX-10726, currently in Phase 1 studies for post-checkpoint inhibitor settings. With $195 million in cash and marketable securities, Compass Therapeutics anticipates funding operations into 2028.
Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary
Compass Therapeutics, Inc. reported its first-quarter 2026 results, showing increased comprehensive and net losses compared to the previous year, as the biopharma company advances several antibody programs. The lead candidate, Tovecimig, met its primary objective in a Phase 2/3 study for biliary tract cancer and received FDA Orphan Drug Designation, with plans for a BLA submission. The company maintains a strong financial position, expected to fund operations into 2028, despite a rise in G&A costs.
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
Canaccord Genuity has maintained a Buy rating on Compass Therapeutics (NASDAQ:CMPX) but lowered its price target to $7 from $13. This decision follows data from the COMPANION-002 trial, where Tovecimig+paclitaxel showed improved progression-free survival, though overall survival interpretation was complicated by a high crossover rate. Stifel and Jefferies also reiterated Buy ratings, with Jefferies noting the 63% stock selloff as an "over-reaction."
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) after its stock price dropped significantly following the announcement of mixed results from a phase 2/3 study of its drug tovecimig. While the study met a key secondary endpoint of progression-free survival, it missed another key secondary endpoint, overall survival. The firm is encouraging investors who purchased Compass securities to connect and assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from a Phase 2/3 study of its drug tovecimig, where the company's stock fell 64.41% after the drug missed a key secondary endpoint of overall survival, despite meeting progression-free survival. The law firm is encouraging investors affected by this news to join their investigation into potential claims.
CMPX Stock Plunges As Traders Weigh Cancer Trial Fallout
Compass Therapeutics Inc. (CMPX) stock plunged by over 60% due to a mixed cancer trial readout for its drug tovecimig, which showed improved response and progression-free survival but missed the overall survival endpoint in the intent-to-treat population due to significant patient crossover. Despite the selloff, many analysts maintain "Buy" ratings, citing the drug's efficacy in a high-unmet-need cancer and the company's strong cash position, with regulatory talks, including a pre-BLA meeting, planned for mid-2026 as the next key catalyst. The stock's current trading reflects market uncertainty and the binary nature of upcoming FDA interactions.
Compass Therapeutics (CMPX) general counsel buys more company stock
Compass Therapeutics' General Counsel, Jonathan Anderman, purchased 25,000 shares of common stock at $1.89 per share in an open-market transaction. This acquisition brings his direct holdings to 196,000 shares, which includes 150,000 unvested restricted stock units vesting in annual installments starting January 2, 2027. The SEC Form 4/A filing also clarifies the transaction code for the purchase.
Compass Therapeutics | DEFA14A: Others
This article provides access to a DEFA14A filing by Compass Therapeutics. These filings are preliminary proxy statements that include important information for shareholders prior to a definitive proxy statement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This investigation stems from the company's announcement of phase 2/3 study results for its drug tovecimig, where a key secondary endpoint (overall survival) was missed, despite meeting another (progression-free survival). Investors who suffered losses are encouraged to contact the firm for potential class action participation.
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This decline occurred after the company announced mixed results from a phase 2/3 study for its drug tovecimig, where it met one key secondary endpoint but missed another, overall survival. The law firm is encouraging affected investors to inquire about the securities investigation.
Compass Therapeutics (CMPX) CAO receives 15,000-share equity grant
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, received a grant of 15,000 common stock shares at $1.89 each on April 29, 2026, increasing his direct holdings to 397,500 shares. This grant, classified under transaction code A, is a compensation award and includes 62,500 unvested restricted stock units vesting annually starting January 2, 2027. The Form 4 filing indicates a neutral impact and sentiment regarding this insider trading activity.
[DEF 14A] Compass Therapeutics, Inc. Definitive Proxy Statement
Compass Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 10, 2026, as a virtual event. Stockholders will vote on the election of two Class III directors, the ratification of CohnReznick LLP as the independent auditor, and non-binding advisory votes on executive compensation and the frequency of future "Say-on-Pay" votes. The proxy statement details executive compensation for 2025, including $5.10 million for CEO Thomas J. Schuetz, and outlines director compensation and corporate governance policies.
[ARS] Compass Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by Compass Therapeutics, Inc. (CMPX) on April 29, 2026, at 08:15 AM. The filing is categorized with low impact and neutral sentiment. It also provides an overview of CMPX's stock data, recent news, and other SEC filings.
Compass Therapeutics (CMPX) Is Down 65.4% After Tovecimig Combo Meets Key BTC Trial Endpoints - What's Changed
Compass Therapeutics' (CMPX) share price is down 65.4% despite its tovecimig drug combination meeting primary and key secondary endpoints in a Phase 2/3 trial for advanced biliary tract cancer. The COMPANION-002 data strengthens the clinical thesis for tovecimig, but the company still faces challenges with its zero revenue base, continued losses, and the need for further funding. Investors are weighing the clinical proof of concept against ongoing cash burn and funding uncertainty, leading to diverse valuations for the stock.
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics will host a webcast on Monday, April 27, 2026, to present topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study. This study evaluated tovecimig, a bispecific antibody, combined with paclitaxel for advanced biliary tract cancer patients. The webcast will provide details on the study's findings and the company's oncology-focused biopharmaceutical pipeline.
CMPX - Compass Therapeutics Inc Stock Price and Quote
Compass Therapeutics Inc.'s stock (CMPX) saw a 4.47% increase, closing at $1.87 on April 28. The company was recently downgraded to Market Perform by Raymond James after survival outcomes from its Phase 3 COMPANION-002 trial for biliary tract cancer. The article provides detailed financial metrics, analyst ratings history, and recent news related to CMPX.
Compass Therapeutics (NASDAQ: CMPX) reports positive tovecimig data in biliary tract cancer trial
Compass Therapeutics announced positive data from its Phase 2/3 COMPANION-002 study of tovecimig plus paclitaxel in second-line biliary tract cancer, showing statistically significant improvements in overall response rate (17.1% vs. 5.3%) and progression-free survival (4.7 months vs. 2.6 months). While overall survival endpoints were confounded by a high crossover rate of control patients to the tovecimig arm, a subset analysis indicated significantly prolonged survival for those who crossed over. The company plans to meet with the FDA to discuss these results for a potential Biologics License Application submission.
Compass Therapeutics Inc (CMPX) Stock Price, Quote, News & History
Compass Therapeutics Inc. (CMPX) stock significantly dropped after its tovecimig trial for bile duct cancer, while showing progression-free survival, missed its overall survival endpoint. Despite this, analysts had previously projected the drug to be a new standard of care, potentially exceeding $1 billion in global sales. The article provides key financial data, analyst ratings, and company information for CMPX.
Compass Therapeutics, Inc. Shareholders Are Encouraged to
Johnson Fistel, PLLP is investigating potential claims against Compass Therapeutics, Inc. (NASDAQ: CMPX) on behalf of investors. This investigation follows the disclosure of data from the COMPANION-002 clinical trial, which showed that the company's lead drug candidate, tovecimig, did not meet its overall survival secondary endpoint, leading to a significant stock price decline. The law firm is evaluating whether Compass Therapeutics complied with federal securities laws and encourages affected investors to contact them for more information on recovering losses.
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Compass Therapeutics' shares fell sharply after its drug tovecimig, for advanced biliary tract cancer, failed to meet the overall survival endpoint in a trial. This was largely due to high crossover from the control arm and prolonged survival of those crossover patients. Despite the setback in overall survival, the drug showed significant improvement in progression-free survival, leading to questions about the data's approvability by the FDA.
US Stocks Mixed; Nasdaq Falls Over 100 Points - Chanson International (NASDAQ:CHSN), Compass Therapeutics
U.S. stocks experienced a mixed trading session, with the Nasdaq Composite dropping over 100 points. Domino's Pizza Inc. reported weaker than expected Q1 financial results, impacting market sentiment. Several individual stocks saw significant movements, including Youxin Technology and US Energy Corp surging, while Compass Therapeutics Inc. and Chanson International Holding declined.
$Compass Therapeutics (CMPX.US)$ fully out! thanks mkt.
An investor, MsNoFomoTrade, announced on the moomoo Community platform that they have fully exited their position in Compass Therapeutics (CMPX.US), expressing gratitude to the market. This post is a personal trading update shared within the investment community.
CMPX Stock Slides As Volatility Grips Compass Therapeutics
Compass Therapeutics Inc. (NASDAQ: CMPX) is experiencing significant stock volatility, with shares dropping by 65.51% due to clinical trial setbacks. The company, a high-risk biotech, despite being in a "spend to build" phase with minimal revenue, has strong cash reserves ($31M in cash, $208M including short-term investments) and low debt. This makes CMPX a speculative "story stock" highly attractive to short-term momentum traders, despite the inherent risks of such rapid price movements.
Compass Therapeutics Inc. tovecimig plus paclitaxel improves median PFS to 4.7 months versus 2.6 months
Compass Therapeutics Inc. announced that its drug combination of tovecimig plus paclitaxel significantly improved median Progression-Free Survival (PFS) to 4.7 months compared to 2.6 months. The article also mentions recent analyst rating changes and other company news, including a fall in shares due to a study falling short on overall survival endpoint in biliary tract cancer. The report details the company's oncology-focused biopharmaceutical pipeline, targeting various disease pathways with antibody-based therapeutics.
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
Compass Therapeutics announced positive full secondary endpoint data from its Phase 2/3 COMPANION-002 trial for tovecimig plus paclitaxel in second-line biliary tract cancer (BTC). The combination significantly improved progression-free survival and overall response rates compared to paclitaxel alone. While overall survival did not reach statistical significance due to high crossover in control patients, the long survival of crossover patients and overall high usage of tovecimig support its potential to become a new standard of care.
